{"filing":{"accession_number":"0001193125-26-265867","cik":"0001691082","ticker":"LBRX","company_name":"LB PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"d221514d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1691082/000119312526265867/d221514d8k.htm"},"events":[{"id":5664,"run_id":4966,"accession_number":"0001193125-26-265867","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Dr. Anna Eramo, Chief Medical Officer, resigned effective June 15, 2026, and will transition to an advisor role. While the filing emphasizes that her departure is not expected to materially impact clinical development activities, the resignation of a CMO at a clinical-stage pharmaceutical company is a material executive departure that investors would consider significant. The separation agreement with severance and equity acceleration further confirms this is a formal executive departure event.","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5882,"accession_number":"0001193125-26-265867","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Dr. Anna Eramo, Chief Medical Officer, resigned effective June 15, 2026, and will transition to an advisor role. While the filing emphasizes that her departure is not expected to materially impact clinical development activities, the resignation of a CMO at a clinical-stage pharmaceutical company is a material executive departure that investors would consider significant. The separation agreement with severance and equity acceleration further confirms this is a formal executive departure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:19:14.335707+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5882,"accession_number":"0001193125-26-265867","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Dr. Anna Eramo, Chief Medical Officer, resigned effective June 15, 2026, and will transition to an advisor role. While the filing emphasizes that her departure is not expected to materially impact clinical development activities, the resignation of a CMO at a clinical-stage pharmaceutical company is a material executive departure that investors would consider significant. The separation agreement with severance and equity acceleration further confirms this is a formal executive departure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:19:14.335707+00:00","company_name":"LB PHARMACEUTICALS INC","ticker":"LBRX","filing_date":"2026-06-10"}]}